NasdaqGS:RGENLife Sciences
The Bull Case For Repligen (RGEN) Could Change Following New Gene Therapy Chromatography Resin Launches
Earlier in 2025, Repligen Corporation expanded its bioprocessing portfolio by launching three high-performance chromatography resins: AVIPure HiPer AAV9 and AAV8 affinity resins, plus the HiPer QA anion exchange resin, aimed at advancing gene therapy purification and process efficiency.
This move strengthens Repligen’s position in next-generation bioprocessing by broadening its consumables offering, potentially increasing recurring revenue as gene therapy pipelines mature.
We’ll now examine...